Compositions and methods for treating an arthritic condition

• US 20050113332A1
• Filed: 11/02/2004
• Published: 05/26/2005
• Est. Priority Date: 12/14/2000
• Status: Abandoned Application

• Current Assignee: Jacob Selhub, Ronenn Roubenoff
• Original Assignee: Jacob Selhub, Ronenn Roubenoff
• Inventors: Roubenoff, Ronenn, Selhub, Jacob
• Application Number:
  US10/980,364
• Publication Number:
  US 20050113332A1
• Time in Patent Office: Days
• US Class Current: 514/52
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 31/714 Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis

Abstract

The present invention features compositions and methods for the treatment of an arthritic condition. The compositions contain a reduced folate compound and a cobalamin compound.

Claims

1. A method of treating an arthritic condition comprising administering to a mammal a composition comprising a reduced folate compound.

2. The method according to claim 1, wherein said arthritic condition comprises osteoarthritis.

3. The method according to claim 1, wherein the composition comprises 0.01 mg to 500 mg of said reduced folate compound.

4. The method according to claim 1, wherein the composition further comprises a cobalamin compound.

5. The method according to claim 4, wherein the composition comprises of 0.0002 mg to 10 mg of said cobalamin compound.

6. The method of claim 1, wherein said composition does not comprise folic acid.

7. The method of claim 5, wherein said composition further comprises a betaine compound.

8. The method according to claim 7, wherein the composition comprises 50 mg to 20,000 mg of said betaine compound.

9. The method of claim 1, wherein said reduced folate compound is 5-methyl tetrahydrofolate.

10. The method of claim 1, wherein said reduce folate compound is 5-formyl tetra hydrofolate.

11. The method of claim 1, wherein said reduced folate is selected from the group consisting of (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, and 5-formimino-(6S)-tetrahydrofolic acid.

12. The method of claim 1, wherein said reduced folate compound is administered at a dose of 0.1-50 mg/day.

13. The method of claim 1, wherein said reduced folate is administered at a dose of 0.1-5 mg/day.

14. The method of claim 4, wherein said cobalamin compound is administered at a dose of 0.002-1 mg/day.

15. The method of claim 7, wherein said betaine compound is administered at a dose of 500-2000 mg/day.

16. A method of alleviating a symptom of arthritis, comprising administering to a mammal a composition comprising a reduced folate compound, wherein said mammal is diagnosed as suffering from or at risk of developing arthritis.

17. The method of claim 16, wherein said mammal is diagnosed as suffering from or at risk of developing osteoarthritis.

18. The method according to claim 16, wherein the composition comprises 0.01 mg to 500 mg of said reduced folate compound.

19. The method according to claim 16, wherein the composition comprises 0.1 mg to 50 mg of said reduced folate compound.

20. The method according to claim 16, wherein the composition comprises 0.1 mg to 5 mg of said reduced folate compound.

21. The method according to claim 16, wherein the composition further comprises a cobalamin compound.

22. The method according to claim 21, wherein the composition comprises of 0.0002 mg to 10 mg of said cobalamin compound.

23. The method according to claim 21, wherein the composition comprises of 0.002 mg to 1 mg of said cobalamin compound.

24. The method of claim 16, wherein said composition does not comprise folic acid.

25. The method of claim 21, wherein said composition further comprises a betaine compound.

26. The method according to claim 25, wherein the composition comprises 50 mg to 20,000 mg of said betaine compound.

27. The method according to claim 25, wherein the composition comprises 500 mg to 2000 mg of said betaine compound.

28. The method of claim 16, wherein said reduced folate compound is 5-methyl-tetrahydrofolate.

29. The method of claim 16, wherein said reduce folate compound is 5-formyl tetra hydrofolate.

30. The method of claim 16, wherein said reduced folate is selected from the group consisting of (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, and 5-formimino-(6S)-tetrahydrofolic acid.

31. The method of claim 16, wherein said reduced folate compound is administered at a dose of 0.1-50 mg/day.

32. The method of claim 16, wherein said reduced folate compound is administered at a dose of 0.1-5 mg/day.

33. The method of claim 21, wherein said cobalamin compound is administered at a dose of 0.002-1 mg/day.

34. The method of claim 25, wherein said betaine compound is administered at a dose of 500-2000 mg/day.